Array BioPharma Inc.
) recently announced positive interim results from a phase I
study which is evaluating its candidate ARRY-520 combined with
Onyx Pharmaceuticals, Inc.
) Kyprolis in patients suffering from relapsed or refractory
multiple myeloma (MM). The results were presented at the 2013
Congress of the European Hematology Association in Sweden.
The study enrolled patients suffering from relapsed or refractory
MM who were unable to tolerate
Takeda Pharmaceutical Company Limited
) Velcade. Interim results from the study revealed that the
combination of ARRY-520 and Kyprolis showed a disease control
rate of 82% along with a clinical benefit rate of 53%. The
results further revealed that the combination was well tolerated
with no serious side effects.
Array also presented data on a potential patient selection marker
from several studies on ARRY-520 in patients suffering from
relapsed and refractory MM.
Array mentioned in its press release that data from a phase II
study on ARRY-520 revealed overall survival was comparatively
longer in patients with low alpha-1-acid glycoprotein (AAG) than
in patients with higher AAG. This is expected to help Array to
target the appropriate patient population who stand to benefit
from ARRY-520 treatment.
We note that Kyprolis is indicated for the treatment of MM
patients who have received at least two prior therapies including
Velcade and an immunomodulatory agent. The disease had progressed
in these patients on or within 60 days of completion of the last
Currently, Array BioPharma carries a Zacks Rank #3 (Hold).
However, biopharma stocks such as
Jazz Pharmaceuticals Public Limited Company
) presently look better positioned with a Zacks Rank #1 (Strong
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.